Exxonmobil Investment Management Inc. TX Decreases Holdings in C R Bard Inc (BCR)

Exxonmobil Investment Management Inc. TX reduced its stake in C R Bard Inc (NYSE:BCR) by 11.0% in the fourth quarter, HoldingsChannel.com reports. The fund owned 11,805 shares of the medical instruments supplier’s stock after selling 1,466 shares during the quarter. Exxonmobil Investment Management Inc. TX’s holdings in C R Bard were worth $3,910,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently modified their holdings of BCR. Monroe Bank & Trust MI boosted its stake in C R Bard by 65.6% in the third quarter. Monroe Bank & Trust MI now owns 447 shares of the medical instruments supplier’s stock valued at $100,000 after acquiring an additional 177 shares during the period. Patten Group Inc. boosted its stake in C R Bard by 66.0% in the third quarter. Patten Group Inc. now owns 556 shares of the medical instruments supplier’s stock valued at $106,000 after acquiring an additional 221 shares during the period. Valeo Financial Advisors LLC acquired a new position in C R Bard in the third quarter valued at approximately $170,000. Captrust Financial Advisors acquired a new position in C R Bard in the second quarter valued at approximately $192,000. Finally, Choate Investment Advisors acquired a new position in C R Bard in the second quarter valued at approximately $201,000. Institutional investors own 79.11% of the company’s stock.

In other news, Vice Chairman John H. Weiland sold 33,435 shares of C R Bard stock in a transaction that occurred on Tuesday, November 7th. The stock was sold at an average price of $333.31, for a total transaction of $11,144,219.85. Following the sale, the insider now owns 76,331 shares of the company’s stock, valued at $25,441,885.61. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Christopher S. Holland sold 38,242 shares of C R Bard stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $334.04, for a total value of $12,774,357.68. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 129,681 shares of company stock worth $43,125,017. Corporate insiders own 0.80% of the company’s stock.

A number of equities analysts have commented on the company. ValuEngine downgraded C R Bard from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Cowen restated a “hold” rating and issued a $317.00 target price on shares of C R Bard in a research note on Friday, November 3rd. Barclays lifted their target price on C R Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a research note on Monday, November 6th. Zacks Investment Research upgraded C R Bard from a “hold” rating to a “buy” rating and set a $372.00 target price for the company in a research note on Tuesday, December 26th. Finally, Needham & Company LLC restated a “hold” rating on shares of C R Bard in a research note on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $311.43.

Shares of C R Bard Inc (BCR) opened at $331.24 on Friday. The firm has a market capitalization of $24,140.00, a P/E ratio of 43.64, a PEG ratio of 2.53 and a beta of 0.52. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.57. C R Bard Inc has a twelve month low of $222.42 and a twelve month high of $337.73.

C R Bard (NYSE:BCR) last released its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.96 by $0.06. The company had revenue of $989.80 million for the quarter, compared to analysts’ expectations of $990.64 million. C R Bard had a return on equity of 19.39% and a net margin of 9.51%. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.64 earnings per share. sell-side analysts forecast that C R Bard Inc will post 11.89 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This article was first posted by Markets Daily and is the property of of Markets Daily. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.themarketsdaily.com/2018/01/12/exxonmobil-investment-management-inc-tx-decreases-holdings-in-c-r-bard-inc-bcr.html.

About C R Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C R Bard Inc (NYSE:BCR).

Institutional Ownership by Quarter for C R Bard (NYSE:BCR)

Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply